Zhengye Biotechnology Holding Limited Announces Financial Results for the First Six Months of Fiscal Year 2026
JILIN, China , Nov. 13, 2026 /PRNewswire/ -- Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the "Company" or "Zhengye"), a veterinary vaccine manufacturer that encompasses research, development, manufacturing, and sales of veterinary vaccines, with a focus on livestock vaccines in China, today announced its unaudited financial results for the six months ended June 30, 2026.
Mr. Songlin Song, co-chief executive officer of Zhengye, remarked, " During the first half of fiscal year 2026, we continued to enhance profitability through disciplined cost management and operational efficiency. Despite the decline in net revenue and gross profit, we are encouraged by the improvement in our gross profit margin to 32.9%, an increase of 1.8 percentage points from 31.1% in the same period last year, primarily reflecting improved margins in our other vaccines segment. Total operating expenses decreased by 22.2% year over year to RMB37.6 million, while our operating loss narrowed by 27.9%. Our net loss also decreased by 13.3% to RMB22.2 million from RMB25.6 million in the same period last year. Looking ahead, we aim to continue prioritizing financial discipline, optimizing our cost structure, and allocating resources efficiently to support sustainable growth and long-term value creation."
Mr. Aiden Han, co-chief executive officer of Zhengye, added, " We remain focused on advancing our long-term growth strategy through the development of high-demand vaccines and expansion into new markets. Building on our existing product development initiatives, we aim to further expand our presence in the household animal vaccine industry, including through the development of vaccines for cats and dogs. On the international front, with our products already exported to Vietnam, Pakistan, and Egypt, we intend to explore additional opportunities in Africa, Central Asia, and West Asia. We also aim to strengthen our ability to attract, incentivize, and retain talented professionals to support our long-term development. We believe these strategic initiatives, together with our established industry experience and technological capabilities, will enhance our competitiveness and support Zhengye's long-term growth."
First Six Months of Fiscal Year 2026 Financial Summary
Net revenue was RMB50.9 million (US$7.5 million) for the six months ended June 30, 2026, compared to RMB62.3 million for the same period last year.
Gross profit was RMB16.7 million (US$2.5 million) for the six months ended June 30, 2026, compared to RMB19.4 million for the same period last year.
Gross profit margin was 32.9% for the six months ended June 30, 2026, an increase of 1.8 percentage points from 31.1% for the same period last year.
Net loss was RMB22.2 million (US$3.3 million) for the six months ended June 30, 2026, compared to RMB25.6 million for the same period last year.
Basic and diluted loss per share was RMB0.40 (US$0.06) for the six months ended June 30, 2026, compared to RMB0.46 for the same period last year.
First Six Months of Fiscal Year 2026 Financial Results
Net Revenue
Net revenue was RMB50.9 million (US$7.5 million) for the six months ended June 30, 2026, representing a decrease of 18.3% from RMB62.3 million for the same period last year.
For the six months ended June 30, (Unaudited)
2025
2026
(in thousands, except for percentages)
Revenues
RMB
%
RMB
US$
%
Swine vaccines
46,706
74.9
38,202
5,630
75.0
Poultry vaccines
7,015
11.3
6,496
957
12.8
Other vaccines
8,607
13.8
6,249
922
12.2
Total revenues
62,328
100
50,947
7,509
100
Revenue from sales of swine vaccines was RMB38.2 million (US$5.6 million) for the six months ended June 30, 2026, decreased from RMB46.7 million for the same period last year. Amid the broader industry environment, cost-cutting requirements from key customers resulted in lower sales volume.
Revenue from sales of poultry vaccines was RMB6.5 million (US$1.0 million) for the six months ended June 30, 2026, decreased from RMB7.0 million for the same period last year. This decline was primarily due to lower sales volume amid weak market demand in the broader industry environment.
Revenue from sales of other vaccines was RMB6.2 million (US$0.9 million) for the six months ended June 30, 2026, decreased from RMB8.6 million for the same period last year. Lower demand from key customers resulted in reduced sales volume.
Cost of Revenue
Cost of revenue was RMB34.2 million (US$5.0 million) for the six months ended June 30, 2026, representing a decrease of 20.4% from RMB42.9 million for the same period last year.
Gross Profit
Gross profit was RMB16.7 million (US$2.5 million) for the six months ended June 30, 2026, decreased from RMB19.4 million for the same period last year.
Gross profit margin was 32.9% for the six months ended June 30, 2026, representing an increase of 1.8 percentage points from 31.1% for the same period last year. The increase in gross profit margin was primarily attributable to other vaccines, the gross profit margin of which improved from negative 20.8% for the six months ended June 30, 2025 to 0.4% for the six months ended June 30, 2026, mainly because the sales volume of sheep vaccines, which carry relatively high unit costs and fixed production costs, decreased amid weak market demand. The gross profit margins of swine vaccines and poultry vaccines remained relatively stable, at 44.3% and negative 2.9%, respectively, for the six months ended June 30, 2026, as compared to 45.9% and negative 3.8%, respectively, for the six months ended June 30, 2025.
Operating Expenses
Total operating expenses were RMB37.6 million (US$5.5 million) for the six months ended June 30, 2026, decreased from RMB48.3 million for the same period last year.
Sales and marketing expenses were RMB18.6 million (US$2.7 million) for the six months ended June 30, 2026, decreased from RMB23.2 million for the same period last year. The decrease in sales and marketing expenses mainly resulted from a decrease in payroll for sales staff and travel expenses.
General and administrative expenses were RMB13.7 million (US$2.0 million) for the six months ended June 30, 2026, decreased from RMB16.8 million for the same period last year. The decrease in administrative expenses was attributed to the decrease in employee compensation, professional service fees and travel expenses. The decrease in professional service fees was mainly because the Company incurred such fees in connection with the preparation for the Company's initial public offering for the six months ended June 30, 2025, while no such fees were incurred for the six months ended June 30, 2026.
Research and development expenses were RMB4.8 million (US$0.7 million) for the six months ended June 30, 2026, decreased from RMB9.0 million for the same period last year. The decrease in research and development expenses mainly resulted from a decrease in development material expenses and the absence of one-time bonuses paid to research and development personnel in connection with the Company's initial public offering in the current period.
Net Loss
Net loss was RMB22.2 million (US$3.3 million) for the six months ended June 30, 2026, decreased from RMB25.6 million for the same period last year.
Basic and Diluted Loss per Share
Basic and diluted loss per share was RMB0.40 (US$0.06) for the six months ended June 30, 2026, compared to RMB0.46 for the same period last year.
Financial Condition
As of June 30, 2026, the Company had cash of RMB31.9 million (US$4.7 million), compared to RMB50.3 million as of December 31, 2025.
Net cash used in operating activities was RMB16.8 million (US$2.5 million) for the six months ended June 30, 2026, compared to RMB14.0 million for the same period last year.
Net cash used in investing activities was RMB5.7 million (US$0.8 million) for the six months ended June 30, 2026, compared to RMB0.7 million for the same period last year.
Net cash provided by financing activities was RMB4.6 million (US$0.7 million) for the six months ended June 30, 2026, compared to RMB 42.3 million for the same period last year.
Exchange Rate Information
This announcement contains translations of certain foreign currency amounts into U.S. dollars for the convenience of the reader. Unless otherwise stated, all translations of Renminbi ("RMB") into U.S. dollars ("US$") were made at RMB6.7851 to US$1.00, the exchange rate set forth in the H.10 statistical release of the Federal Reserve Board on June 30, 2026.
About Zhengye Biotechnology Holding Limited
Through Jilin Zhengye Biological Products Co., Ltd., the Company's operating entity based in Jilin, China, Zhengye Biotechnology Holding Limited focuses on the research, development, manufacturing, and sales of veterinary vaccines, with an emphasis on vaccines for livestock. For over 20 years, the operating entity has been committed to enhancing the health of animals. The operating entity has 50 veterinary vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs. The operating entity's products are available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan, and Egypt as of the date of this press release. The operating entity has three veterinary vaccine production floors (including 13 vaccine production lines), one quality examination center, and one animal facility for vaccine development, all operating in accordance with Good Manufacturing Practices for Veterinary Drugs issued by the Ministry of Agriculture and Rural Affairs of the PRC. For more information, please visit the Company's website: http://ir.jlzybio.com .
Forward-Looking Statements
This announcement contains statements that may constitute "forward-looking" statements which are made pursuant to the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Investors can find many (but not all) of these statements by the use of words such as "approximates," "believes," "hopes," "expects," "anticipates," "estimates," "projects," "intends," "plans," "will," "would," "should," "could," "may" or other similar expressions in this announcement. Statements that are not historical facts, including statements about the Company's beliefs, plans, and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the United States Securities and Exchange Commission.
For more information, please contact:
Zhengye Biotechnology Holding Limited Investor Relations Department Email: ir@jlzybio.com
Ascent Investor Relations LLC Tina Xiao Phone: +1-646-932-7242 Email: investors@ascent-ir.com
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (Amounts in thousands of RMB and US$, except for number of shares)
As of
December 31, 2025
June 30, 2026
RMB
RMB
US$
ASSETS
Current assets:
Cash
50,332
31,884
4,699
Restricted cash
2
2
-
Short-term investments
1,560
1,284
189
Notes receivable, net
-
467
69
Accounts receivable, net
18,485
24,865
3,665
Advance to suppliers
2,208
1,233
182
Advance to suppliers-a related party
-
16
2
Inventories, net
39,166
40,339
5,945
Prepayments and other current assets, net
25,667
24,808
3,656
Total current assets
137,420
124,898
18,407
Non-current assets:
Property, plant and equipment, net
236,812
226,431
33,372
Land use rights, net
7,673
7,544
1,112
Intangible assets, net
47,084
50,766
7,482
Right-of-use assets, net
469
412
61
Long-term prepayments
7,014
1,935
285
Total non-current assets
299,052
287,088
42,312
Total assets
436,472
411,986
60,719
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Short-term loans
65,100
69,374
10,224
Current maturities of long-term loans
700
700
103
Derivative liabilities
-
1,050
155
Operating lease liabilities-current
106
25
4
Accounts payable
44,010
38,878
5,728
Contract liabilities
4,752
3,405
502
Taxes payable
2,345
2,774
409
Accrued expenses and other liabilities
3,463
3,572
527
Total current liabilities
120,476
119,778
17,652
Non-current liabilities:
Long-term loans
8,850
8,500
1,253
Operating lease liabilities-non-current
327
296
44
Deferred tax liabilities
104
-
-
Total non-current liabilities
9,281
8,796
1,297
Total liabilities
129,757
128,574
18,949
Commitments and contingencies
-
-
-
Shareholders' equity:
Class A ordinary shares (US$0.000025 par value; 1,900,000,000 shares authorized; 7,391,376 and 7,391,376 shares issued and outstanding as of December 31, 2025 and June 30, 2026, respectively)
1
1
-
Class B ordinary shares (US$0.000025 par value; 100,000,000 shares authorized; 40,000,000 and 40,000,000 shares issued and outstanding as of December 31, 2025 and June 30, 2026, respectively)
7
7
1
Additional paid-in capital
240,752
240,752
35,482
Statutory reserves
32,647
32,647
4,812
Retained deficit
(21,633)
(40,549)
(5,976)
Accumulated other comprehensive income
(1,926)
(3,066)
(452)
Total Zhengye Biotechnology Holding Limited's shareholders' equity
249,848
229,792
33,867
Noncontrolling interests
56,867
53,620
7,903
Total equity
306,715
283,412
41,770
Total liabilities and equity
436,472
411,986
60,719
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Amounts in thousands of RMB and US$, except for number of shares and per share data)
For the six months ended June 30,
2025
2026
RMB
RMB
USD
Net revenues
62,328
50,947
7,509
Cost of revenues
(42,944)
(34,198)
(5,040)
Gross profit
19,384
16,749
2,469
Sales and marketing expenses
(23,243)
(18,629)
(2,746)
General and administrative expenses
(16,770)
(13,703)
(2,020)
Research and development expenses
(8,969)
(4,770)
(703)
Reversal of (provision for) credit losses
719
(470)
(69)
Total operating expenses
(48,263)
(37,572)
(5,538)
Operating loss
(28,879)
(20,823)
(3,069)
Other income (expenses):
Interest income
72
11
2
Interest expense
(1,752)
(1,565)
(231)
Unrealized gains (losses) on marketable equity securities and derivative instruments
588
(1,326)
(195)
Unrealized foreign exchange gain (loss)
(1,421)
627
92
Government subsidy
502
893
132
Other expenses
-
(79)
(12)
Total other expenses, net
(2,011)
(1,439)
(212)
Loss before income taxes
(30,890)
(22,262)
(3,281)
Income tax benefits
5,340
99
14
Net loss
(25,550)
(22,163)
(3,267)
Net loss attributable to noncontrolling interests
3,882
3,247
479
Net loss attributable to the Zhengye Biotechnology Holding Limited's shareholders
(21,668)
(18,916)
(2,788)
Comprehensive loss
Net loss
(25,550)
(22,163)
(3,267)
Other comprehensive loss
Foreign currency translation adjustment
(969)
(1,140)
(168)
Total comprehensive loss
(26,519)
(23,303)
(3,435)
Total comprehensive loss attributable to non-controlling interest
3,882
3,247
479
Total comprehensive loss attributable to the Zhengye Biotechnology Holding Limited's shareholders
(22,637)
(20,056)
(2,956)
Loss per share:
-Basic and diluted – Class A Ordinary shares
(0.46)
(0.40)
(0.06)
-Basic and diluted – Class B Ordinary shares
(0.46)
(0.40)
(0.06)
Weighted average shares outstanding used in calculating basic and diluted earnings per share:
Ordinary shares – basic and diluted
47,316,793
47,391,376
47,391,376
Basic and diluted – Class A Ordinary shares
7,316,793
7,391,376
7,391,376
Basic and diluted – Class B Ordinary shares
40,000,000
40,000,000
40,000,000
ZHENGYE BIOTECHNOLOGY HOLDING LIMITED UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands of RMB and US$, except for number of shares)
For the six months ended June 30,
2025
2026
RMB
RMB
US$
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss
(25,550)
(22,163)
(3,267)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization
12,251
14,021
2,067
Amortization of operating lease right-of-use assets
-
52
8
Provision for (reversal of) credit losses
(719)
470
69
Impairment for inventory
4,115
8,444
1,244
Deferred tax benefits
(5,340)
(104)
(15)
Unrealized (gains) losses on marketable equity securities and derivative instruments
(588)
1,326
195
Unrealized foreign exchange (gain) loss
1,421
(627)
(92)
Changes in operating assets and liabilities:
Notes receivable
(99)
(470)
(69)
Accounts receivable
23,336
(6,874)
(1,013)
Advance to suppliers
(1,572)
975
144
Advance to suppliers-a related party
-
(16)
(2)
Inventories
554
(9,616)
(1,417)
Prepayments and other current assets
(23,379)
189
28
Other receivable -a related party
738
-
-
Operating lease liabilities
-
(107)
(16)
Accounts payable
(1,513)
(1,505)
(223)
Contract liabilities
1,516
(1,347)
(199)
Taxes payable
115
429
63
Accrued expenses and other liabilities
746
110
17
Net cash used in operating activities
(13,968)
(16,813)
(2,478)
CASH FLOWS FROM INVESTING ACTIVITIES
Loans to a related party
(7,000)
-
-
Loan repayment from a related party
7,000
-
-
Purchase of property, plant and equipment
(255)
(3,377)
(498)
Prepayment for purchase of intangible assets
(409)
(2,360)
(348)
Net cash used in investing activities
(664)
(5,737)
(846)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from loans
41,910
46,810
6,899
Repayment of loans
(44,000)
(42,260)
(6,228)
Repayment to a related party
(146)
-
-
Proceeds from initial public offering
43,081
-
-
Shareholder contribution
1,470
-
-
Net cash provided by financing activities
42,315
4,550
671
Effect of exchange rate changes on cash and restricted cash
(680)
(448)
(66)
Net increase (decrease) in cash and restricted cash
27,003
(18,448)
(2,719)
Cash and restricted cash at beginning of period
18,606
50,334
7,418
Cash and restricted cash at end of period
45,609
31,886
4,699
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for:
Interest
1,700
1,564
231
Income taxes
-
5
1
NON-CASH INVESTING AND FINANCING ACTIVITIES:
Liabilities assumed in connection with purchase of property, plant and equipment
1,521
151
22
Derecognition of right-of-use asset and lease liability due to operating lease modification
-
5
1
Reclassification of deferred initial public offering cost into additional paid-in capital
8,663
-
-